EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Sixty years of experience with hereditary transthyretin amyloidosis: Insights from the Swedish transthyretin amyloidosis registry

Lotta Stenberg, Björn Pilebro, Intissar Anan, Jorge Mejia Baranda, Kristin Samuelsson, Per Eldhagen, Rolf Backlund, Jonas Wixner

Journal of Internal Medicine · 2025

DOI: 10.1111/joim.70020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Internal Medicine, 2025. Verfasst von Lotta Stenberg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Västerbotten Läns Landsting.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hereditary transthyretin (ATTRv) amyloidosis was first described in Sweden in the late 1960s. Selected patient data have been collected since then and have now been transferred to a national quality registry.

Methods

This is the first report from SveATTR—a longitudinal Swedish web‐based registry open for TTR variant carriers and patients with ATTR amyloidosis. The registry covers basic background information, as well as relevant clinical follow‐up measures and data on disease‐modifying therapies. Data from all ATTRv amyloidosis patients registered through December 2022 were included.

Results

In total, 1055 patients were included, of whom 65% were males and 95% carried the V30M variant. Median age of onset was 64 years, and 79% had a late disease onset (≥50 years). Eighty‐seven percent of the patients had peripheral polyneuropathy at onset, whereas 10% had cardiac symptoms, 8% had visual disturbances, and 6% had gastrointestinal symptoms. A total of 159 patients had undergone liver transplantation, and 233 had received a disease‐modifying drug. Improved survival was seen for transplanted patients and for patients on drug therapy.

Conclusion

This report highlights the importance of SveATTR for further characterization of the Swedish ATTRv amyloidosis population as well as for evaluating the efficacy of disease‐modifying therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialHumansSwedenMaleRegistriesFemaleMiddle AgedAgedAdultAge of OnsetPrealbuminLongitudinal StudiesLiver TransplantationAged, 80 and over

Stichwörter der Autor:innen

drug therapieshereditary amyloidosisliver transplantationregistrysurvivaltransthyretin

Substanzen

Prealbumin

Autor:innen und Institutionen

  • Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
  • Department of Medicine, Norrland's University Hospital, Umeå, Sweden.
  • Department of Medicine, Piteå Hospital, Piteå, Sweden.
  • Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Förderung

  • Västerbotten Läns Landsting

Zitieren

APA

Stenberg, L., Pilebro, B., Anan, I., Baranda, J. M., Samuelsson, K., Eldhagen, P., Backlund, R., & Wixner, J. (2025). Sixty years of experience with hereditary transthyretin amyloidosis: Insights from the Swedish transthyretin amyloidosis registry. Journal of Internal Medicine. https://doi.org/10.1111/joim.70020

Vancouver

Stenberg L, Pilebro B, Anan I, Baranda JM, Samuelsson K, Eldhagen P, et al. Sixty years of experience with hereditary transthyretin amyloidosis: Insights from the Swedish transthyretin amyloidosis registry. Journal of Internal Medicine. 2025. doi:10.1111/joim.70020

BibTeX
@article{Stenberg2025,
  author = {Stenberg, Lotta and Pilebro, Björn and Anan, Intissar and Baranda, Jorge Mejia and Samuelsson, Kristin and Eldhagen, Per and Backlund, Rolf and Wixner, Jonas},
  title = {Sixty years of experience with hereditary transthyretin amyloidosis: Insights from the Swedish transthyretin amyloidosis registry},
  journal = {Journal of Internal Medicine},
  year = {2025},
  doi = {10.1111/joim.70020}
}
Kostenlos starten →